Quantitative BCR-ABL1 RQ-PCR fusion transcript monitoring in chronic myelogenous leukemia

Franklin R. Moore, Carole B. Rempfer, Richard Press

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Citations (Scopus)

Abstract

The reciprocal Philadelphia translocation between chromosomes 9 and 22 [t(9;22)(q34;q11)] creates a BCR-ABL1 fusion protein that occurs in approximately 95% of cases of chronic myelogenous leukemia (CML), 15% of cases of adult acute lymphoblastic leukemia, and 5% of adult cases of acute myeloid leukemia. The BCR-ABL1 protein is a constitutively activated tyrosine kinase that induces and maintains the neoplastic phenotype in these leukemias. PCR-based methods to identify and quantitate the tumor-specific BCR-ABL1 RNA have been shown to be an ultrasensitive diagnostic/prognostic tool for Philadelphia-positive leukemias. A novel tyrosine kinase inhibitor (TKI), imatinib, has been confirmed as an effective targeted treatment in most CML patients. A consensus goal for TKI treatment is to achieve a major molecular response (MMR), defined as a 3-log (1,000-fold) reduction in BCR-ABL1 transcripts. Patients who achieve an MMR have been shown to have a significantly reduced risk of disease progression. Conversely, increasing post-therapy BCR-ABL1 RNA levels convey a significantly increased risk of disease progression. The early identification of these high-risk patients may allow early changes to the therapeutic strategy, before frank relapse. Thus, quantitative measurement of BCR-ABL1 transcripts in blood and bone marrow both aids in the initial diagnosis of CML and is essential for routine post-therapy minimal residual disease monitoring. We describe here a method for quantitating BCR-ABL1 transcripts in peripheral blood or bone marrow of CML patients using real-time quantitative reverse transcription PCR (RQ-PCR).

Original languageEnglish (US)
Title of host publicationMethods in Molecular Biology
Pages1-23
Number of pages23
Volume999
DOIs
StatePublished - 2013

Publication series

NameMethods in Molecular Biology
Volume999
ISSN (Print)10643745

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Polymerase Chain Reaction
Protein-Tyrosine Kinases
Disease Progression
Leukemia
Bone Marrow
RNA
Therapeutics
Chromosomes, Human, Pair 22
Chromosomes, Human, Pair 9
Residual Neoplasm
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia
Reverse Transcription
Proteins
Phenotype
Recurrence
Neoplasms

Keywords

  • BCR-ABL1
  • Chronic myelogenous leukemia
  • Imatinib
  • Major molecular response
  • Philadelphia chromosome

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Cite this

Moore, F. R., Rempfer, C. B., & Press, R. (2013). Quantitative BCR-ABL1 RQ-PCR fusion transcript monitoring in chronic myelogenous leukemia. In Methods in Molecular Biology (Vol. 999, pp. 1-23). (Methods in Molecular Biology; Vol. 999). https://doi.org/10.1007/978-1-62703-357-2-1

Quantitative BCR-ABL1 RQ-PCR fusion transcript monitoring in chronic myelogenous leukemia. / Moore, Franklin R.; Rempfer, Carole B.; Press, Richard.

Methods in Molecular Biology. Vol. 999 2013. p. 1-23 (Methods in Molecular Biology; Vol. 999).

Research output: Chapter in Book/Report/Conference proceedingChapter

Moore, FR, Rempfer, CB & Press, R 2013, Quantitative BCR-ABL1 RQ-PCR fusion transcript monitoring in chronic myelogenous leukemia. in Methods in Molecular Biology. vol. 999, Methods in Molecular Biology, vol. 999, pp. 1-23. https://doi.org/10.1007/978-1-62703-357-2-1
Moore FR, Rempfer CB, Press R. Quantitative BCR-ABL1 RQ-PCR fusion transcript monitoring in chronic myelogenous leukemia. In Methods in Molecular Biology. Vol. 999. 2013. p. 1-23. (Methods in Molecular Biology). https://doi.org/10.1007/978-1-62703-357-2-1
Moore, Franklin R. ; Rempfer, Carole B. ; Press, Richard. / Quantitative BCR-ABL1 RQ-PCR fusion transcript monitoring in chronic myelogenous leukemia. Methods in Molecular Biology. Vol. 999 2013. pp. 1-23 (Methods in Molecular Biology).
@inbook{c9703a19263a4711887a834a2c72fb1a,
title = "Quantitative BCR-ABL1 RQ-PCR fusion transcript monitoring in chronic myelogenous leukemia",
abstract = "The reciprocal Philadelphia translocation between chromosomes 9 and 22 [t(9;22)(q34;q11)] creates a BCR-ABL1 fusion protein that occurs in approximately 95{\%} of cases of chronic myelogenous leukemia (CML), 15{\%} of cases of adult acute lymphoblastic leukemia, and 5{\%} of adult cases of acute myeloid leukemia. The BCR-ABL1 protein is a constitutively activated tyrosine kinase that induces and maintains the neoplastic phenotype in these leukemias. PCR-based methods to identify and quantitate the tumor-specific BCR-ABL1 RNA have been shown to be an ultrasensitive diagnostic/prognostic tool for Philadelphia-positive leukemias. A novel tyrosine kinase inhibitor (TKI), imatinib, has been confirmed as an effective targeted treatment in most CML patients. A consensus goal for TKI treatment is to achieve a major molecular response (MMR), defined as a 3-log (1,000-fold) reduction in BCR-ABL1 transcripts. Patients who achieve an MMR have been shown to have a significantly reduced risk of disease progression. Conversely, increasing post-therapy BCR-ABL1 RNA levels convey a significantly increased risk of disease progression. The early identification of these high-risk patients may allow early changes to the therapeutic strategy, before frank relapse. Thus, quantitative measurement of BCR-ABL1 transcripts in blood and bone marrow both aids in the initial diagnosis of CML and is essential for routine post-therapy minimal residual disease monitoring. We describe here a method for quantitating BCR-ABL1 transcripts in peripheral blood or bone marrow of CML patients using real-time quantitative reverse transcription PCR (RQ-PCR).",
keywords = "BCR-ABL1, Chronic myelogenous leukemia, Imatinib, Major molecular response, Philadelphia chromosome",
author = "Moore, {Franklin R.} and Rempfer, {Carole B.} and Richard Press",
year = "2013",
doi = "10.1007/978-1-62703-357-2-1",
language = "English (US)",
isbn = "9781627033565",
volume = "999",
series = "Methods in Molecular Biology",
pages = "1--23",
booktitle = "Methods in Molecular Biology",

}

TY - CHAP

T1 - Quantitative BCR-ABL1 RQ-PCR fusion transcript monitoring in chronic myelogenous leukemia

AU - Moore, Franklin R.

AU - Rempfer, Carole B.

AU - Press, Richard

PY - 2013

Y1 - 2013

N2 - The reciprocal Philadelphia translocation between chromosomes 9 and 22 [t(9;22)(q34;q11)] creates a BCR-ABL1 fusion protein that occurs in approximately 95% of cases of chronic myelogenous leukemia (CML), 15% of cases of adult acute lymphoblastic leukemia, and 5% of adult cases of acute myeloid leukemia. The BCR-ABL1 protein is a constitutively activated tyrosine kinase that induces and maintains the neoplastic phenotype in these leukemias. PCR-based methods to identify and quantitate the tumor-specific BCR-ABL1 RNA have been shown to be an ultrasensitive diagnostic/prognostic tool for Philadelphia-positive leukemias. A novel tyrosine kinase inhibitor (TKI), imatinib, has been confirmed as an effective targeted treatment in most CML patients. A consensus goal for TKI treatment is to achieve a major molecular response (MMR), defined as a 3-log (1,000-fold) reduction in BCR-ABL1 transcripts. Patients who achieve an MMR have been shown to have a significantly reduced risk of disease progression. Conversely, increasing post-therapy BCR-ABL1 RNA levels convey a significantly increased risk of disease progression. The early identification of these high-risk patients may allow early changes to the therapeutic strategy, before frank relapse. Thus, quantitative measurement of BCR-ABL1 transcripts in blood and bone marrow both aids in the initial diagnosis of CML and is essential for routine post-therapy minimal residual disease monitoring. We describe here a method for quantitating BCR-ABL1 transcripts in peripheral blood or bone marrow of CML patients using real-time quantitative reverse transcription PCR (RQ-PCR).

AB - The reciprocal Philadelphia translocation between chromosomes 9 and 22 [t(9;22)(q34;q11)] creates a BCR-ABL1 fusion protein that occurs in approximately 95% of cases of chronic myelogenous leukemia (CML), 15% of cases of adult acute lymphoblastic leukemia, and 5% of adult cases of acute myeloid leukemia. The BCR-ABL1 protein is a constitutively activated tyrosine kinase that induces and maintains the neoplastic phenotype in these leukemias. PCR-based methods to identify and quantitate the tumor-specific BCR-ABL1 RNA have been shown to be an ultrasensitive diagnostic/prognostic tool for Philadelphia-positive leukemias. A novel tyrosine kinase inhibitor (TKI), imatinib, has been confirmed as an effective targeted treatment in most CML patients. A consensus goal for TKI treatment is to achieve a major molecular response (MMR), defined as a 3-log (1,000-fold) reduction in BCR-ABL1 transcripts. Patients who achieve an MMR have been shown to have a significantly reduced risk of disease progression. Conversely, increasing post-therapy BCR-ABL1 RNA levels convey a significantly increased risk of disease progression. The early identification of these high-risk patients may allow early changes to the therapeutic strategy, before frank relapse. Thus, quantitative measurement of BCR-ABL1 transcripts in blood and bone marrow both aids in the initial diagnosis of CML and is essential for routine post-therapy minimal residual disease monitoring. We describe here a method for quantitating BCR-ABL1 transcripts in peripheral blood or bone marrow of CML patients using real-time quantitative reverse transcription PCR (RQ-PCR).

KW - BCR-ABL1

KW - Chronic myelogenous leukemia

KW - Imatinib

KW - Major molecular response

KW - Philadelphia chromosome

UR - http://www.scopus.com/inward/record.url?scp=84883255822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883255822&partnerID=8YFLogxK

U2 - 10.1007/978-1-62703-357-2-1

DO - 10.1007/978-1-62703-357-2-1

M3 - Chapter

SN - 9781627033565

VL - 999

T3 - Methods in Molecular Biology

SP - 1

EP - 23

BT - Methods in Molecular Biology

ER -